Functional Monitoring after Trabeculectomy or XEN Microstent Implantation Using Spectral Domain Optical Coherence Tomography and Visual Field Indices—A Retrospective Comparative Cohort Study

Abstract

Simple Summary Primary open-angle glaucoma leads to a loss of retinal ganglion cells and a reduction in the retinal nerve fiber layer thickness, consequently leading to the development and growth of visual field defects. In its final stages, this results in visual loss and irreversible blindness if not treated adequately. A reduction in the intraocular pressure by means of medication and/or surgery is the only known treatment option for slowing, or at best, arresting disease progression. This study demonstrates that trabeculectomy and XEN microstent implantation are nearly equally effective techniques for reducing intraocular pressure and stabilizing visual acuity and pre-developed visual field defects over a follow-up period of 24 months after surgery. However, further analysis using spectral domain optical coherence tomography revealed that disease progression occurs in terms of further retinal nerve fiber layer loss after both trabeculectomy and XEN microstent implantation. Abstract The aim of this study was to compare the efficacy of trabeculectomy (TE), single XEN microstent implantation (solo XEN) or combined XEN implantation and cataract surgery (combined XEN) in primary open-angle glaucoma cases, naïve to prior surgical treatment, using a monocentric retrospective comparative cohort study. Intraocular pressure (IOP) and the number of IOP-lowering drugs (Meds) were monitored during the first 24 months after surgery. Further disease progression was monitored using peripapillary retinal nerve fiber layer (RNFL) thickness examinations using spectral domain optical coherence tomography (OCT) as well as visual acuity (VA) and visual field (VF) tests. In the TE group (52 eyes), the mean IOP decreased from 24.9 ± 5.9 to 13.9 ± 4.2 mmHg (p < 0.001) and Meds decreased from 3.2 ± 1.2 to 0.5 ± 1.1 (p < 0.001). In the solo XEN (38 eyes) and the combined XEN groups, the mean IOP decreased from 24.1 ± 4.7 to 15.7 ± 3.0 mmHg (p < 0.001) and 25.4 ± 5.6 to 14.7 ± 3.2 mmHg (p < 0.001), while Meds decreased from 3.3 ± 0.8 to 0.8 ± 1.2 (p < 0.001) and 2.7 ± 1.2 to 0.4 ± 1.0 (p < 0.001), respectively. The VF and VA indices showed no sign of further deterioration, the RNFL thickness further decreased in all treatment groups after surgery. TE and XEN led to comparable reductions in IOP and Meds. Although the VA and VF indices remained unaltered, the RNFL thickness continuously decreased in all treatment groups during the 24-month follow-up.